BP000990-PKA-239: Recombinant Human VEGFR1 D5
Source: Insect Cells-derived.
The activity of FLT1 D5 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces. The ED50 for this effect is typically 10 ng/ml, corresponding to a specific activity of 100,000IU/mg.
Purity > 90%, by RP-HPLC and SDS-PAGE.BP000991-PKA-241: Recombinant Human VEGFR1 D17
Source: Insect Cells-derived.
The activity of FLT1/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells. The ED50 for this effect is typically 10-30 ng/ml, corresponding to a specific activity of 33,333.33-100,000 units/mg.
Purity > 95%, by SDS-PAGE.BP000992-PKA-240: Recombinant Human VEGFR1
Source: Insect Cells-derived.
The activity of FLT1 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surface receptors. The ED50 for this effect is typically 10 ng/ml, corresponding to a specific activity of 100,000IU/mg.
Purity > 90%, by RP-HPLC and SDS-PAGE.BP000992-PKA-354: Recombinant Human VEGFR1, His Tag
Source: E. coli-derived.
Purity > 95%, by SDS-PAGE.BP000993-PKA-244: Recombinant Human VEGFR3
Source: Insect Cells-derived.
Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 ng/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml.
Purity > 90%, by RP-HPLC and SDS-PAGE.BP000993-PKA-245: Recombinant Human VEGFR3 Fc Chimera
Source: Insect Cells-derived.
Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 ?/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml.
Purity > 90%, by RP-HPLC and SDS-PAGE.BP000995-PKA-242: Recombinant Human VEGFR2
Source:Insect Cells-derived.
The activity of VEGFR2 D1-7 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml, corresponding to a specific activity of 100,000 IU/mg.
Purity > 95%, by SDS-PAGE.BP000995-PKA-243: Recombinant Human VEGFR2 Fc Chimera
Source:Insect Cells-derived.
The activity of sVEGFR-2/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells. The ED50 for this effect is typically 10-30 ng/ml, corresponding to a specific activity of 33,333.33-100,000 units/mg.
Purity > 90%, by SDS-PAGE.BP001900-PRO-1044: Recombinant Human Vps20-Associated 1 Homolog (VTA1) Protein
Source: E. coli-derived.
Purity: > 95.0% as determined by SDS-PAGE.BP002094-PRO-200: Recombinant Human Vesicular overexpressed in cancer prosurvival protein 1 (VOPP1) Protein
Source: E. coli-derived.
Purity: > 90% as determined by SDS-PAGE.